Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 4/20 | 0.69 |
| ▸ | RORC | P51449 | 3/20 | 0.69 |
| ▸ | USP2 | O75604 | 2/20 | 0.69 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.69 |
| ▸ | OSBP2 | Q969R2 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.69 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.58 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.58 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.57 |
| ▸ | POLA1 | P09884 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.56 |
| ▸ | FNTB | P49356 | 1/20 | 0.56 |
| ▸ | CRYAB | P02511 | 1/20 | 0.55 |
| ▸ | HMGCR | P04035 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.55 |
| ▸ | ITGAV | P06756 | 1/20 | 0.55 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288702 | 1.00 | OSBP (0.69) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL28750282 | 1.00 | OSBP (0.69) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL289374 | 1.00 | OSBP (0.69) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL1917363 | 1.00 | OSBP (0.69) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL6390184 | 1.00 | OSBP (0.69) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL6387159 | 1.00 | OSBP (0.69) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL3350440 | 1.00 | OSBP (0.69) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL336002 | 1.00 | OSBP (0.69) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL22032772 | 1.00 | OSBP (0.69) | OSBPRORCUSP2CYP46A1OSBP2 | |
| SCHEMBL26642855 | 1.00 | OSBP (0.69) | OSBPRORCUSP2CYP46A1OSBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380574-A2 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | Buck Institute for Research on Aging (US) | 2024-06-12 | — | — | EP | claimed |
| WO-2023014718-A2 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2023-02-09 | — | — | WO | claimed |
| EP-2592420-B1 | Method and use of metabolic compounds for diagnosing stroke | INFANDX AG (DE) | 2017-09-20 | — | — | EP | claimed |
| WO-2011006087-A1 | INHIBITION OF PPAR GAMMA EXPRESSION IN PREADIPOCYTE CELLS BY OXYSTEROLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-13 | — | — | WO | claimed |
| US-20100112030-A1 | ROLE OF HEDGEHOG SIGNALING IN ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-06 | — | — | US | claimed |
| EP-2146724-A2 | ROLE OF HEDGEHOG SIGNALING IN ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE | The Regent of the University of California (US) | 2010-01-27 | — | — | EP | claimed |
| EP-2111225-A2 | INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS | The Regents Of The University Of California (US) | 2009-10-28 | — | — | EP | claimed |
| US-20090202660-A1 | Agents and Methods for Osteogenic Oxysterols Inhibition of Oxidative Stress on Osteogenic Cellular Differentiation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-13 | — | — | US | claimed |
| WO-2008115469-A2 | ROLE OF HEDGEHOG SIGNALING IN ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-25 | — | — | WO | claimed |
| WO-2008082520-A2 | INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-10 | — | — | WO | claimed |
| WO-2006110490-A2 | AGENTS AND METHODS FOR OSTEOGENIC OXYSTEROLS INHIBITION OF OXIDATIVE STRESS ON OSTEOGENIC CELLULAR DIFFERENTIATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-10-19 | — | — | WO | claimed |
| US-6184215-B1 | TOPICALLY APPLYING TO SKIN A HYDROXYCHOLESTEROL TO ACTIVATE LIVER-BASED X-ACTIVATED RECEPTOR ALPHA (LXRA) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-06 | — | — | US | claimed |
| WO-2000049992-A2 | USE OF FXR, PPARα AND LXRα ACTIVATORS TO TREAT ACNE/ACNEIFORM CONDITIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-08-31 | — | — | WO | claimed |
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260078086-A1 | VERSATILE BIODEGRADABLE MOLECULES AS NUCLEIC ACID CARRIERS | TIBA BIOTECH LLC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260069540-A1 | GENE DELIVERY AGENTS | TIBA BIOTECH LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-0904538-A1 | METHOD OF DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS USING ANTI-CHOLESTEROL ANTIBODIES | EntreMed, Inc. (US) | 1999-03-31 | — | — | EP | disclosed |
| EP-0784681-A1 | METHOD OF USING A SCAVENGER RECEPTOR IN THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1997021099-A1 | METHOD OF DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS USING ANTI-CHOLESTEROL ANTIBODIES | ENTREMED, INC. (US) | 1997-06-12 | — | — | WO | disclosed |
| WO-1996011268-A1 | METHOD OF USING A SCAVENGER RECEPTOR IN THE TREATMENT OF ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069540-A1 | GENE DELIVERY AGENTS | LIPC, L3MBTL1, L3MBTL3 | OSBP 833/4885RORC 2445/4885USP2 1837/4885 |
| US-20100112030-A1 | ROLE OF HEDGEHOG SIGNALING IN ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE | SHH, SMO, GLI1 | OSBP 14/4885RORC 134/4885USP2 1120/4885 |
| US-20260078086-A1 | VERSATILE BIODEGRADABLE MOLECULES AS NUCLEIC ACID CARRIERS | NSUN2, SMC1A, SSU72 | OSBP 267/4885RORC 4796/4885USP2 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.